Per cent neutrophils in bronchoalveolar lavage at baseline and final visit (week 12) for the intention-to-treat (ITT) (n=28/46) and Completer (n=25/33) populations, by treatment allocation
| n | Baseline Median (IQR) | Final visit Median (IQR) | Change from baseline Median (IQR) | |
|---|---|---|---|---|
| ITT azithromycin | 13/23 | 16.6 (4.2 to 68.8) | 32.0 (10.0 to 69.5) | 9.8 (−10.4 to 17.7) |
| ITT placebo | 15/23 | 14.8 (2.4 to 56.0) | 19.8 (2.0 to 52.2) | −0.5 (−7.8 to 5.0) |
| Completers azithromycin | 12/16 | 16.1 (3.7 to 61.5) | 31.5 (7.5 to 73.3) | 11.9 (−7.7 to 18.9) |
| Completers placebo | 13/17 | 9.2 (2.0 to 52.5) | 19.8 (1.5 to 46.9) | −0.5 (−7.5 to 4.9) |